Editas MedicineEDIT -2.14%51 Forward Dividend Yield % is 0.00% as of Jun. 25, 2026. GuruFocus rates EDIT with a GF Score™ of 51/100 and a GF Value™ of $1.92 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 146 Biotechnology companies, Editas Medicine ranks worse than 684930.82% on this metric.
As of today (2026-06-25), the Forward Annual Dividend Yield of Editas Medicine is 0.00%.
As of today (2026-06-25), the Trailing Annual Dividend Yield of Editas Medicine is 0.00%.
EDIT's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.495 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Editas Medicine (NAS:EDIT) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Editas Medicine Forward Dividend Yield % Related Terms
EDIT vs PRTA, XOMA, FDMT: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, Editas Medicine's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Editas Medicine Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Editas Medicine's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Editas Medicine's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Editas Medicine (EDIT) has a Forward Dividend Yield % of 0.00% as of Jun. 25, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Editas Medicine and its competitors. According to the industry distribution chart, Editas Medicine ranks #999999 out of 146 companies in the Biotechnology industry.
Is Editas Medicine's Forward Dividend Yield % too high?
Editas Medicine's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Editas Medicine ranks #999999 out of 146 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Editas Medicine has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Editas Medicine's Forward Dividend Yield % compare to PRTA and XOMA?
According to the Biotechnology industry distribution chart, Editas Medicine ranks #999999 out of 146 companies for Forward Dividend Yield %. This places Editas Medicine in the lower half of its industry. The industry median Forward Dividend Yield % is 1.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.50, based on 146 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Editas Medicine and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Editas Medicine's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Editas Medicine stock overvalued right now?
Based on GuruFocus' analysis, Editas Medicine (EDIT) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.92, compared to a current price of $2.74 — trading 42.7% above its estimated fair value. The current Forward Dividend Yield % is 0.00%. Editas Medicine's overall GF Score™ is 51/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Editas Medicine (EDIT), the current Forward Dividend Yield % is 0.00% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Editas Medicine (EDIT) Overvalued in 2026?
Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued.
The current stock price of $2.74 is trading 42.7% above its estimated GF Value™ of $1.92.
GuruFocus considers Editas Medicine to be Significantly Overvalued.
Key valuation signals for EDIT:
Forward Dividend Yield %: 0.00%
GF Value™: $1.92 vs. price of $2.74 (42.7% above fair value)
No single metric tells the full story. See the EDIT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
51GF Score
Get the complete analysis for EDIT
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EDIT has been successfully added to your 